These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 7207155)
1. [Problems in testing new drugs in the hospital and general practice (phase III)]. Blumenbach L Med Welt; 1981 Feb; 32(7):210-2. PubMed ID: 7207155 [No Abstract] [Full Text] [Related]
3. Report on the fifth consensus conference: methodology of long-term clinical trials in psychiatry. Angst J; Bech P; Bruinvels J; Engel RR; Ferner U; Guelfi JD; Lingjaerde O; Müller-Oerlinghausen B; Paes de Sousa M; Paykel E Pharmacopsychiatry; 1994 May; 27(3):101-7. PubMed ID: 8078950 [No Abstract] [Full Text] [Related]
4. Research in general practice in New Zealand. Reid J N Z Med J; 2003 Nov; 116(1186):U679. PubMed ID: 14657962 [No Abstract] [Full Text] [Related]
5. [Evaluation of consequences of written informed consent on physician-patient relations. Apropos of Huriet's law]. Gérard JP; Romestaing P; Marquis I; Wagner JP; Maillot MH; Buatois F; Bohas C Bull Cancer; 1993 Oct; 80(10):903-4. PubMed ID: 8204933 [No Abstract] [Full Text] [Related]
6. Informed consent. "Blanket" consent to trials would be a good idea. Brewin T BMJ; 1997 Jul; 315(7102):253. PubMed ID: 9253296 [No Abstract] [Full Text] [Related]
7. Methodological/ethical issues and general practice research. Piterman L Aust Fam Physician; 2000 Sep; 29(9):890-1. PubMed ID: 11008398 [No Abstract] [Full Text] [Related]
8. [Difficulties with conducting clinical trials in France]. Zannad F; Plétan Y Therapie; 2001; 56(4):341-7. PubMed ID: 11677850 [TBL] [Abstract][Full Text] [Related]
10. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design. Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F; Circulation; 2004 Jun; 109(21):e302-4. PubMed ID: 15173052 [No Abstract] [Full Text] [Related]
11. Methodological and design issues in clinical trials of new neuroleptics: an overview. Awad AG Br J Psychiatry Suppl; 1993 Dec; (22):51-7. PubMed ID: 7906524 [TBL] [Abstract][Full Text] [Related]
13. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846 [TBL] [Abstract][Full Text] [Related]
14. Advantages and drawbacks of the Zelen design for randomized clinical trials. Horwitz RI; Feinstein AR J Clin Pharmacol; 1980 Jul; 20(7):425-7. PubMed ID: 7430410 [No Abstract] [Full Text] [Related]
15. Methodologic considerations for trials of lung cancer prophylaxis. Miller AB Can Med Assoc J; 1980 Apr; 122(7):776-9. PubMed ID: 7363245 [TBL] [Abstract][Full Text] [Related]
16. [Informed consent, what information is left after a therapeutic trial?]. Gallet M; Aupetit JF; Servan E; Lestaevel M; Lopez M; Chassoux G Arch Mal Coeur Vaiss; 1994 Jan; 87(1):39-45. PubMed ID: 7811150 [TBL] [Abstract][Full Text] [Related]
17. [Multiple practice research. Experience with some methods]. Bennedsen H; Nielsen JV Ugeskr Laeger; 1979 May; 141(22):1482-4. PubMed ID: 377745 [No Abstract] [Full Text] [Related]
18. [Testing of drugs in general practice]. Naess K Tidsskr Nor Laegeforen; 1976 Aug; 96(23):1186-7. PubMed ID: 788225 [No Abstract] [Full Text] [Related]
19. Randomized clinical trials and research strategy. Simon R Cancer Treat Rep; 1982 May; 66(5):1083-7. PubMed ID: 7083212 [No Abstract] [Full Text] [Related]